Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study

NCT ID: NCT02540109

Last Updated: 2023-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

58 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-31

Study Completion Date

2019-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase II study aims to ascertain the effectiveness of HD-tDCS for adjunctive treatment of anomia in chronic aphasia post stroke. Furthermore, it will help explore factors such as alternate outcome measures, subject selection criteria, and benefits of extended treatment duration. These results will be compared to an existing trial using conventional non-targeted tDCS with the same design and outcomes. Patients will be treated with HD-tDCS while performing computerized anomia treatment. The basis behind this method is that language therapy is mediated by cortical areas that are most effectively activated during the training tasks, thus increasing electric stimulation in these areas may improve learning outcomes. To better understand the long term benefits of the adjunctive treatment, patients will be screened again four weeks and six months after study using the same anomia tests. If HD-tDCS shows promising results in increasing the learning outcomes of anomia treatment, a Phase III trial can be considered.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Aphasia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Stroke Anomia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High-Definition tDCS (Active)

Group Type EXPERIMENTAL

HD-tDCS (Soterix Medical, Active)

Intervention Type DEVICE

Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.

High-Definition tDCS (Sham)

Group Type EXPERIMENTAL

HD-tDCS (Soterix Medical, Sham)

Intervention Type DEVICE

Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HD-tDCS (Soterix Medical, Active)

Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.

Intervention Type DEVICE

HD-tDCS (Soterix Medical, Sham)

Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Soterix Medical High-Definition MxN stimulator Soterix Medical HDTargets Soterix Medical High-Definition MxN stimulator Soterix Medical HDTargets

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* one-time ischemic stroke in the left hemisphere
* greater than 6-months post-stroke onset
* between 25 and 75 years of age
* aphasia diagnosis (as determined by pre-treatment language-based testing)
* right-handed (before the stroke)
* native speaker of English
* ability to provide informed written or verbal consent

Exclusion Criteria

* clinically reported history of dementia, alcohol abuse, psychiatric disorder, traumatic brain injury, or extensive visual acuity or visual-spatial problems
* factors contraindicative of tDCS administration (sensitive scalp, previous brain surgery)
* prior history of epileptic or unprovoked seizures occurring during the previous 12 months.
* Presence of Metal implants of claustrophobia (not able to undergo MRI)
* Pregnancy
* Presence of any other neurological disease than stroke
* Childhood history of speech, language, hearing, or intellectual impairment
Minimum Eligible Age

25 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

Sponsor Role collaborator

Georgetown University

OTHER

Sponsor Role collaborator

University of North Carolina, Chapel Hill

OTHER

Sponsor Role collaborator

The City College of New York

OTHER

Sponsor Role collaborator

Medstar Health Research Institute

OTHER

Sponsor Role collaborator

University of South Carolina

OTHER

Sponsor Role collaborator

Soterix Medical

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Abhishek Datta, Ph.D

Role: STUDY_CHAIR

Soterix Medical Inc.

Lucas C Parra, Ph.D

Role: STUDY_CHAIR

City University of New York - CCNY

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Georgetown University Medical Center (Peter Turkeltaub, MD, Ph.D.)

Washington D.C., District of Columbia, United States

Site Status

University of North Carolina School of Medicine (Adam Jacks, Ph.D.)

Chapel Hill, North Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://www.ncbi.nlm.nih.gov/pubmed/25547776

Feasibility of using high-definition transcranial direct current stimulation (HD-tDCS) to enhance treatment outcomes in persons with aphasia.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R44NS092144

Identifier Type: NIH

Identifier Source: secondary_id

View Link

SMI092144-P2

Identifier Type: -

Identifier Source: org_study_id